Search Result

Results for "

low-density lipoprotein

" in MedChemExpress (MCE) Product Catalog:

By Targets:	LDLR (42) LOX-1 (1) Acyltransferase (2) Adrenergic Receptor (8) Akt (2) AMPK (1) Antibiotic (2) Apical Sodium-Dependent Bile Acid Transporter (1) Apolipoprotein (3) Apoptosis (16) ASK1 (1) Autophagy (20) Bacterial (9) Biochemical Assay Reagents (2) Calcium Channel (3) Caspase (1) CETP (6) COX (2) Cytochrome P450 (2) Drug Isomer (1) Drug Metabolite (1) Endogenous Metabolite (17) Epigenetic Reader Domain (1) ERK (3) Estrogen Receptor/ERR (1) Farnesyl Transferase (1) Ferroptosis (6) FOXO (1) Fungal (1) FXR (5) G protein-coupled Bile Acid Receptor 1 (1) GLP Receptor (1) Glutathione Peroxidase (5) GPR109A (1) Hedgehog (1) HMG-CoA Reductase (HMGCR) (25) Imidazoline Receptor (8) Interleukin Related (4) Isotope-Labeled Compounds (14) JNK (1) Keap1-Nrf2 (2) Liposome (2) LPL Receptor (2) LXR (2) Microsomal Triglyceride Transfer Protein (MTP) (2) Mitochondrial Metabolism (1) Mitophagy (8) MMP (3) mTOR (1) Necroptosis (1) NF-κB (3) p38 MAPK (4) PCSK9 (16) Peptide-Drug Conjugates (PDCs) (2) PKA (2) Platelet-activating Factor Receptor (PAFR) (2) Potassium Channel (10) PPAR (4) Protease Activated Receptor (PAR) (1) Proteasome (1) Proton Pump (1) RAR/RXR (1) Reactive Oxygen Species (ROS) (8) Reference Standards (13) ROR (4) Smo (1) SOD (1) Thrombin (1) Thyroid Hormone Receptor (6) TNF Receptor (1) VEGFR (2) Virus Protease (1) β-catenin (1)
By Research Areas:	Cancer (29) Cardiovascular Disease (69) Endocrinology (7) Infection (4) Inflammation/Immunology (23) Metabolic Disease (94) Neurological Disease (21)
Oligonucleotides:	Cholesterol (1)

154

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Protéines recombinantes

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: LDLR LOX-1

Cat. No.	Nom du produit	Target	Áreas de investigación	Chemical Structure

HY-17504

Rosuvastatin Calcium 20+ Cited Publications Rosuvastatin hemicalcium; ZD 4522 Calcium	HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial	Cardiovascular Disease Metabolic Disease Cancer
Rosuvastatin Calcium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Calcium potently blocks hERG current with an IC₅₀ of 195 nM . Rosuvastatin Calcium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Calcium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-113046

5-Methyltetrahydrofolic acid Maximum Cited Publications 9 Publications Verification 5-Methyl THF; 5-MTHF	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
5-Methyltetrahydrofolic acid (5-Methyl THF) is the main circulating form of folic acid in the body and is involved in a variety of biochemical reactions. 5-Methyltetrahydrofolic acid regulates cardiovascular function by increasing the production of endothelin-1 (ET-1) in low-density lipoprotein-treated endothelial cells and can be used in the study of cardiovascular diseases .

HY-10626

T0901317 40+ Cited Publications	LXR FXR ROR Apoptosis	Cardiovascular Disease Metabolic Disease Cancer
T0901317 is an orally active and highly selective LXR agonist with an EC₅₀ of 20 nM for LXRα . T0901317 activates FXR with an EC₅₀ of 5 μM . T0901317 is RORα and RORγ dual inverse agonist with K_i values of 132 nM and 51 nM, respectively . T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice .

HY-17504A

Rosuvastatin 20+ Cited Publications ZD 4522	HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial	Cardiovascular Disease Metabolic Disease Cancer
Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC₅₀ of 11 nM. Rosuvastatin potently blocks hERG current with an IC₅₀ of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-112490

Atorvastatin calcium hydrate Maximum Cited Publications 65 Publications Verification	HMG-CoA Reductase (HMGCR)	Cardiovascular Disease Others
Atorvastatin calcium salt trihydrate is a drug belonging to the statin class of drugs used to lower blood cholesterol levels. Atorvastatin calcium salt trihydrate has unique chemical properties that make it an effective tool in controlling high levels of low-density lipoprotein (LDL) cholesterol and triglycerides in the body, reducing the risk of heart attack and stroke. Atorvastatin calcium salt trihydrate works by inhibiting HMG-CoA reductase, the enzyme responsible for producing cholesterol in the liver.

HY-B0144A

Pitavastatin 10+ Cited Publications NK-104	HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC₅₀ of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .

HY-NP013

*Oxidized low density* lipoprotein (mouse)** Mouse ox-LDL	LDLR ROR β-catenin	Cardiovascular Disease
Oxidized low density lipoprotein (mouse) (Mouse ox-LDL) is an oxidized low density lipoprotein (LDL). Oxidized low density lipoprotein (mouse) induces atherosclerosis (AS) by facilitating endothelial dysfunction and accelerating the VSMCs growth and migration. Oxidized low density lipoprotein (mouse) can be used to construct an in vitro model of AS .

HY-112540B

Acetoacetic acid sodium	Endogenous Metabolite	Metabolic Disease
Acetoacetic acid sodium is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid sodium induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid sodium can be used to study metabolic diseases .

HY-B0144

Pitavastatin Calcium 10+ Cited Publications NK-104 hemicalcium; Pitavastatin hemicalcium	HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC₅₀ of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin Calcium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .

HY-N0483

Phillygenin 4 Publications Verification Phillygenol; Epipinoresinol methyl ether; (+)-Phillygenin	Reactive Oxygen Species (ROS)	Others
Phillygenin (Phillygenol) is an active ingredient from Forsythia with many medicinal properties, such as antioxidant, reducing blood lipid, inhibition of low density lipoprotein oxidation.

HY-17504B

Rosuvastatin Sodium 20+ Cited Publications ZD 4522 Sodium; X-Plended Sodium; Crestor Sodium	HMG-CoA Reductase (HMGCR) Potassium Channel Autophagy Bacterial	Cardiovascular Disease Metabolic Disease Cancer
Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC₅₀ of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-P99646

Golocdacimab 2 Publications Verification MEDI6570	LOX-1	Metabolic Disease Inflammation/Immunology
Gocdacimab (MEDI6570) is a fully human IgG1 monoclonal antibody inhibitor targeting the *lectin-like oxidized low-density* lipoprotein receptor LOX-1.** By binding to LOX-1 and blocking its function, gocdacimab effectively reduces the level of free soluble LOX-1, thereby inhibiting key pathological processes such as lipid accumulation, foam cell formation, and vascular wall inflammation. Gocdacimab can interfere with atherosclerosis-related mechanisms, and it is used for research on atherosclerosis, and type 2 diabetes mellitus .

HY-16274

Lapaquistat acetate 1 Publications Verification TAK-475	Farnesyl Transferase	Metabolic Disease
Lapaquistat acetate (TAK-475) is a squalene synthase inhibitor, blocking the conversion of farnesyl diphosphate (FPP) to squalene in the cholesterol biosynthesis pathway . Lapaquistat acetate is effective at lowering low-density lipoprotein cholesterol, but it might cause liver damage. Lapaquistat acetate is used for hypercholesterolemia and mevalonate kinase deficiency (MKD) research .

HY-14668

Lomitapide mesylate 5+ Cited Publications AEGR-733 mesylate; BMS-201038 mesylate	Microsomal Triglyceride Transfer Protein (MTP) mTOR LDLR Autophagy Apoptosis	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Lomitapide (AEGR-733; BMS-201038) mesylate is an orally active microsomal triglyceride transfer protein (MTP) inhibitor and a selective mTORC1 inhibitor with lipid-lowering activity and BBB permeability. Lomitapide mesylate significantly reduces plasma LDL levels by blocking the assembly and secretion of very-low-density lipoprotein (VLDL). Lomitapide mesylate inhibits mTORC1 in an ATP-dependent manner, thereby inducing AMPK-independent autophagic cell death and suppressing cancer cell growth and apoptosis. Lomitapide mesylate also enhances tumor infiltration of CD8 ⁺ T cells. In addition, Lomitapide mesylate inhibits HDAC, improves endothelial function, effectively alleviates vascular inflammation and oxidative stress, and exerts neuroprotective effects in a cerebral ischemia/reperfusion injury model. Lomitapide mesylate can be used in research on related diseases such as colorectal cancer, breast cancer, melanoma, ischemic stroke, and familial hypercholesterolemia .

HY-112540

Acetoacetic acid 4 Publications Verification	Endogenous Metabolite	Metabolic Disease
Acetoacetic acid is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid can be used to study metabolic diseases .

HY-109523

Cerivastatin sodium 2 Publications Verification	HMG-CoA Reductase (HMGCR) Ferroptosis	Cardiovascular Disease Cancer
Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .

HY-W510159

5-O-Methylembelin	PCSK9	Cardiovascular Disease
5-O-Methylembelin is a natural isocoumarin that inhibits PCSK9, *inducible degrader of the low-density* lipoprotein receptor (IDLR), and sterol regulatory element binding protein 2 (SREBP2)** mRNA expression .

HY-N0627

Kaempferol-7-O-β-D-glucopyranoside	LDLR	Others
Kaempferol-7-O-β-D-glucopyranoside is a flavonoid glycoside. Kaempferol-7-O-β-D-glucopyranoside exists in the root bark of Cudrania tricuspidata. Kaempferol-7-O-β-D-glucopyranoside inhibits Cu ²⁺-induced lipid peroxidation of low-density lipoprotein. Kaempferol-7-O-β-D-glucopyranoside possesses antioxidant activity and scavenges DPPH free radicals .

HY-112540A

Acetoacetic acid lithium 4 Publications Verification	Endogenous Metabolite	Metabolic Disease
Acetoacetic acid lithium is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid lithium induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid lithium can be used to study metabolic diseases .

HY-145001

20-HC-Me-Pyrrolidine	LDLR CETP	Metabolic Disease
20-HC-Me-Pyrrolidine (compound AI-3d) is a potent Aster protein inhibitor with IC₅₀s of 0.11 μM, 0.06 μM, and 0.71 μM for Aster-A, Aster-B, and Aster-C, respectively. 20-HC-Me-Pyrrolidine blocks the ability of Asters to bind and transfer cholesterol. 20-HC-Me-Pyrrolidine also inhibits the movement of low-density lipoprotein (LDL) cholesterol to the endoplasmic reticulum (ER) .

HY-P10502

L57	LDLR	Infection
L57 is a low-density lipoprotein receptor-related protein 1 (LRP1)-binding peptide. L57 exhibits high affinity for LRP1, with an EC₅₀ of 45 nM. L57 possesses blood-brain barrier (BBB) permeability and plasma stability. L57 can serve as a carrier for central nervous system drug delivery .

HY-115486

MPO-IN-28 3 Publications Verification	Glutathione Peroxidase	Cardiovascular Disease
MPO-IN-28 is a selective myeloperoxidase (MPO) inhibitor with an IC₅₀ of 44 nM. MPO-IN-28 can effectively inhibit MPO-mediated low-density lipoprotein oxidation with an IC₅₀ of 90 nM .

HY-126356

1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine	Liposome	Cardiovascular Disease
1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine is a major phospholipid in low-density lipoprotein and belongs to the group of 1-acyl phosphatidylcholines. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine does not induce morphological changes in washed human platelets. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine can be used for the research of atherosclerosis and thrombotic diseases .

HY-P99793

Orticumab MLDL1278A	LDLR	Inflammation/Immunology
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized **low-density lipoproteins (oxLDL**). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement .

HY-W007347

1,2-Cyclohexanedione	Biochemical Assay Reagents LDLR	Cardiovascular Disease Metabolic Disease
1,2-Cyclohexanedione is an arginine modification reagent. 1,2-Cyclohexanedione interferes with the degradation of low-density lipoprotein by modifying the arginine group in apolipoprotein. 1,2-Cyclohexanedione can be used in the research of familial hypercholesterolemia .

HY-10473

Eprotirome KB2115	Thyroid Hormone Receptor	Metabolic Disease Endocrinology
Eprotirome (KB2115) is a liver-selective thyroid hormone receptor (TR) agonist. KB2115 has modestly higher affinity for TRβ than for TRα. Eprotirome reduces low-density lipoprotein (LDL) cholesterol concentrations. Eprotirome can be used for dyslipidemias and obesity research .

HY-B0374

Moxonidine BDF5895	Imidazoline Receptor Adrenergic Receptor LDLR	Cardiovascular Disease Neurological Disease
Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I₁-R) agonist. Moxonidine activates imidazoline I₁ receptors and α₂ adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis .

HY-N5015

Rosmanol 1 Publications Verification	COX	Inflammation/Immunology Cancer
Rosmanol could inhibit the oxidation of low density lipoprotein (LPL) and significantly inhibit lipopolysaccharide induced iNOS and COX-2 expression, with anti-inflammatory effect.

HY-P99822

Recaticimab SHR-1209	PCSK9	Metabolic Disease
Recaticimab (SHR-1209) is a humanized IgG1 mAb that selectively targets PCSK9. Recaticimab reduces low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), triglyceride (TG), and lipoprotein(a) levels. Recaticimab can be used for hyperlipidemia research .

HY-109567

Gemcabene PD-72953	LDLR	Metabolic Disease Inflammation/Immunology
Gemcabene (PD-72953), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity .

HY-116175

BIBB 515	LDLR	Metabolic Disease
BIBB 515 is a potent, selective and orally active 2,3-oxidosqualene cyclase (OSC) inhibitor with ED₅₀ values of 0.2-0.5 mg/kg and 0.36-33.3 mg/kg in rats and mice (1-5 hours), respectively. BIBB 515 exerts lipid-lowering effect mainly by inhibiting the production of low-density lipoprotein (LDL) .

HY-B0374A

Moxonidine hydrochloride BDF5895 hydrochloride	Imidazoline Receptor Adrenergic Receptor LDLR	Cardiovascular Disease Neurological Disease
Moxonidine (BDF5895) hydrochloride is an orally active imidazoline type 1 receptor (I₁-R) agonist. Moxonidine hydrochloride activates imidazoline I₁ receptors and α₂ adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine hydrochloride reduces atherosclerotic lesions and lowers blood pressure. Moxonidine hydrochloride can be used in the study of hypertension, heart failure, and atherosclerosis .

HY-19749

PD 151746 5+ Cited Publications	Proteasome Interleukin Related	Cardiovascular Disease Inflammation/Immunology Cancer
PD 151746 is a selective calpain-1 inhibitor with an IC₅₀ of 260 nM. PD 151746 binds μ-calpain Ca ²⁺-binding sites, and shows selectivity over cathepsin B, papain, trypsin, thermolysin, and basal calcineurin. PD 151746 reduces Oxidized low-density lipoprotein (oxLDL)-induced cytotoxicity, apoptotic DNA fragmentation, and blocks IL-1α maturation. PD 151746 can be used for the research of atherosclerosis and psoriasis .

HY-130576

POVPC	Apoptosis	Cardiovascular Disease
POVPC is an oxidized phospholipid can be found in in oxidatively modified low density lipoprotein (oxLDL). POVPC inhibits VSMC growth in high serum condition. POVPC induces apoptosis in low serum condition .

HY-P10502A

L57 acetate	LDLR	Others
L57 acetate is a Low-density lipoprotein receptor-related protein 1 (LRP1)-binding peptide. L57 acetate exhibits high affinity to LRP1 with K_i of 45 nM. L57 acetate exhibits blood-brain barrier (BBB) permeability and plasma stability. L57 acetate can be utilized as the carrier for CNS drug delivery .

HY-113269

alpha-CEHC 1 Publications Verification	Drug Metabolite	Others
alpha-CEHC is a water-soluble metabolite of alpha-tocopherol (α-TOH) with potential antioxidant activity. alpha-CEHC slightly inhibits macrophage-induced low-density lipoprotein (LDL) oxidation, and its inhibitory potency is concentration-dependent .

HY-130245

PCSK9 degrader 1	PCSK9	Metabolic Disease
PCSK9 degrader 1 (Compound 16) is a small molecule ligand for proprotein convertase substilisin-like/kexin type 9 (PCSK9) and shows high affinity to PCSK9 with a K_i of 107 nM. PCSK9 degrader 1 can involve in a protein-protein interaction with the low-density lipoprotein (LDL) receptor .

HY-148758

PCSK9-IN-13	PCSK9	Cardiovascular Disease Metabolic Disease
PCSK9-IN-13(compound 3f) is a potent PCSK9 inhibitor, which can antagonize low-density lipoprotein (LDL) receptor binding by binding to PCSK9, with an IC₅₀ of 537 nM .

HY-N2339

Cholesteryl behenate 1 Publications Verification Cholesteryl docosanoate; Cholesterol behenate	Endogenous Metabolite	Metabolic Disease
Cholesteryl behenate is a cholesterol ester associated with the neutral core of low density lipoprotein Receptor-LDL complexes are taken up by lysosomes and hydrolyzed to release cholesterol from the esters.

HY-17504R

Rosuvastatin Calcium (Standard) 10+ Cited Publications Rosuvastatin hemicalcium (Standard); ZD 4522 Calcium (Standard)	Reference Standards HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial	Cardiovascular Disease Metabolic Disease Cancer
Rosuvastatin (Calcium) (Standard) is the analytical standard of Rosuvastatin (Calcium). This product is intended for research and analytical applications. Rosuvastatin Calcium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Calcium potently blocks hERG current with an IC₅₀ of 195 nM . Rosuvastatin Calcium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Calcium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-129458

Cerivastatin	HMG-CoA Reductase (HMGCR) Ferroptosis	Cardiovascular Disease Cancer
Cerivastatin is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin reduces low-density lipoprotein cholesterol levels. Cerivastatin also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .

HY-W423578

LDLR regulator-1	LDLR	Cardiovascular Disease
LDLR regulator-1 (Compound 7b) is a regulator of the low-density lipoprotein receptor (LDLR), capable of increasing the mRNA expression of LDLR .

HY-172661

Kylo-0603	Thyroid Hormone Receptor Interleukin Related LDLR	Infection Metabolic Disease
KYLO-0603 is an orally active, selective THR-β agonist (EC₅₀ : 31.07 nM). KYLO-0603 has significant activity in lowering serum cholesterol and low-density lipoprotein cholesterol. KYLO-0603 upregulates the expression of THR-regulated genes (including iodothyronine deiodinase 1 (Dio1), malic enzyme 1 (Me1), and thyroid hormone response (Thrsp) gene) and inhibits the expression of inflammatory and fibrotic genes (low-density lipoprotein receptor (LDL-R) gene) by activating THR-β receptors. KYLO-0603 can be used to treat metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis research .

HY-B0144AS1

Pitavastatin-d5 sodium NK-104-d5 sodium	Apoptosis HMG-CoA Reductase (HMGCR) Mitophagy Autophagy	Metabolic Disease Cancer
Pitavastatin-d₅ (sodium) is the deuterium labeled Pitavastatin sodium. Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity.

HY-P11071

PCSK9 Inhibitor, EGF-A	PCSK9	Cardiovascular Disease
PCSK9 Inhibitor, EGF-A is a PCSK9 inhibitor. PCSK9 Inhibitor, EGF-A is residues 293-334 of the EGF-A domain of the low-density lipoprotein (LDL) receptor. PCSK9 Inhibitor, EGF-A can prevent PCSK9-induced intracellular LDLR degradation. PCSK9 Inhibitor, EGF-A can be used in the study of hypercholesterolemia and premature atherosclerosis .

HY-134154

PAz-PC PAzePC; Azelaoyl PC; 1-Palmitoyl-2-Azelaoyl PC	Endogenous Metabolite	Metabolic Disease
Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species which are cytotoxic and pro-atherogenic. Many of these substances were isolated and purified from oxLDL and identified as phosphatidylcholine species containing a fragmented, oxidized short-chain fatty acid remnant at the sn-2 position. PAz-PC (Azelaoyl PC) is one of the predominant oxLDL species and may be one of the important structural determinants of oxLDL.

HY-B0144B

Pitavastatin sodium NK-104 sodium	HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Pitavastatin (NK-104) sodium is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin sodium inhibits cholesterol synthesis from acetic acid with an IC₅₀ of 5.8 nM in HepG2 cells. Pitavastatin sodium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin sodium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .

HY-113046S1

5-Methyltetrahydrofolic acid-13C6 5-Methyl THF-¹³C₆; 5-MTHF-¹³C₆	Isotope-Labeled Compounds Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
5-Methyltetrahydrofolic acid- ¹³C₆ (5-Methyl THF- ¹³C₆) is ¹³C labeled 5-Methyltetrahydrofolic acid. 5-Methyltetrahydrofolic acid (5-Methyl THF) is the main circulating form of folic acid in the body and is involved in a variety of biochemical reactions. 5-Methyltetrahydrofolic acid regulates cardiovascular function by increasing the production of endothelin-1 (ET-1) in low-density lipoprotein-treated endothelial cells and can be used in the study of cardiovascular diseases .

HY-148626

CVI-LM001	PCSK9	Metabolic Disease
CVI-LM001 is an inhibitor PCSK 9. CVI-LM001 inhibits the interaction of PCSK9 with low-density lipoprotein receptor (LDLR), regulates the level of low-density lipoprotein cholesterol (LDL-C) in the blood, and exhibits lipid-lowering efficacy .

HY-120651

LDL-IN-2	LDLR	Metabolic Disease
LDL-IN-2 (compound 3) is an antioxidant against copper mediated low-density lipoproteins (LDL) oxidation .

Cat. No.	Nom du produit	Type

HY-139414

Lysophosphatidylcholines 5+ Cited Publications	Biochemical Assay Reagents
Lysophosphatidylcholines is an orally active lysolipid and a component of oxidized low density lipoprotein (LDL). Lysophosphatidylcholines induces cell injury, the production of IL-1β and apoptosis. Lysophosphatidylcholines has a proactive effect on sepsis .

HY-NP013

*Oxidized low density* lipoprotein (mouse)** Mouse ox-LDL	Biochemical Assay Reagents
Oxidized low density lipoprotein (mouse) (Mouse ox-LDL) is an oxidized low density lipoprotein (LDL). Oxidized low density lipoprotein (mouse) induces atherosclerosis (AS) by facilitating endothelial dysfunction and accelerating the VSMCs growth and migration. Oxidized low density lipoprotein (mouse) can be used to construct an in vitro model of AS .

HY-126726

KOdiA-PC

Biochemical Assay Reagents

Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species that are cytotoxic and proatherogenic. Many of these species were recently isolated and purified from oxLDL and identified as phosphatidylcholine species containing fragmented oxidized short-chain fatty acid residues at the sn-2 position. 1-(Palmitoyl)-2-(5-keto-6-octene-dioyl)phosphatidylcholine or KOdiA-PC is one of the most potent CD36 ligands of the oxLDL species. KOdiA-PC confers CD36 scavenger receptor binding affinity to LDL at a frequency of only 2 to 3 KOdiA-PC molecules/LDL particle and may be one of the more important structural determinants of oxLDL.

Cat. No.	Nom du produit	Target	Research Area

HY-P4073

ANG1005 GRN1005; Paclitaxel trevatide	Peptide-Drug Conjugates (PDCs) LDLR	Cancer
ANG1005 (Paclitaxel trevatide) is a brain-penetrating peptide-drug conjugate. ANG1005, a taxane derivative, consists of three paclitaxel (HY-B0015) molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via low density lipoprotein receptor-related protein (LRP1) transport system .

HY-P10502

L57	LDLR	Infection
L57 is a low-density lipoprotein receptor-related protein 1 (LRP1)-binding peptide. L57 exhibits high affinity for LRP1, with an EC₅₀ of 45 nM. L57 possesses blood-brain barrier (BBB) permeability and plasma stability. L57 can serve as a carrier for central nervous system drug delivery .

HY-P10502A

L57 acetate	LDLR	Others
L57 acetate is a Low-density lipoprotein receptor-related protein 1 (LRP1)-binding peptide. L57 acetate exhibits high affinity to LRP1 with K_i of 45 nM. L57 acetate exhibits blood-brain barrier (BBB) permeability and plasma stability. L57 acetate can be utilized as the carrier for CNS drug delivery .

HY-P10697A

VH4127 TFA	LDLR	Metabolic Disease
VH4127 TFA is a cyclic peptide targeting the low density lipoprotein receptor (LDLR) with a K_D of 18 nM for hLDLR. VH4127 TFA specifically binds to rodent and human epidermal growth factor (EGF) homology domain of LDLR .

HY-P11071

PCSK9 Inhibitor, EGF-A	PCSK9	Cardiovascular Disease
PCSK9 Inhibitor, EGF-A is a PCSK9 inhibitor. PCSK9 Inhibitor, EGF-A is residues 293-334 of the EGF-A domain of the low-density lipoprotein (LDL) receptor. PCSK9 Inhibitor, EGF-A can prevent PCSK9-induced intracellular LDLR degradation. PCSK9 Inhibitor, EGF-A can be used in the study of hypercholesterolemia and premature atherosclerosis .

HY-P10698

VH-N412	Peptide-Drug Conjugates (PDCs) LDLR	Neurological Disease
VH-N412 is a vectorized neuropeptide (NT) with good blood-brain barrier permeability. VH-N412 binds to the low-density lipoprotein receptor (LDLR) and neuropeptide receptor 1 (NTSR-1), and acts as a pharmacological-induced hypothermia (PIH) inducer. VH-N412 exhibits anticonvulsant and neuroprotective effects, and can be used in the study of neurological diseases such as epilepsy.

HY-P10697

VH4127	LDLR	Metabolic Disease
VH4127 is a cyclic peptide targeting the low density lipoprotein receptor (LDLR) with a K_D of 18 nM for hLDLR. VH4127, bearing non-natural amino acid residues, specifically binds to rodent and human epidermal growth factor (EGF) homology domain of LDLR .

HY-P10911

IETP2	LDLR	Others
IETP2 targets low-density lipoprotein receptor-related protein 1 (LRP1) with a K_D of 738 nM and can be used for drug- and imaging agents delivery across the blood-labyrinth barrier (BLB) .

HY-W1126955

Enlicitide (decanoate) MK-0616 (decanoate)	PCSK9	Metabolic Disease Inflammation/Immunology
Enlicitide (MK-0616) decanoate is an orally active macrocyclic peptide PCSK9 inhibitor. Enlicitide decanoate binds to PCSK9, blocks its interaction with low-density lipoprotein receptor (LDLR), and enhances hepatic clearance of LDL-C. Enlicitide decanoate reduces atherogenic lipoproteins, including non-HDL cholesterol, apolipoprotein B, and lipoprotein (a). Enlicitide decanoate is applicable to research related to hypercholesterolemia, heterozygous familial hypercholesterolemia, and atherosclerotic cardiovascular disease .

Cat. No.	Nom du produit	Target	Research Area	Image

HY-P99646

Golocdacimab 2 Publications Verification MEDI6570	LOX-1	Metabolic Disease Inflammation/Immunology
Gocdacimab (MEDI6570) is a fully human IgG1 monoclonal antibody inhibitor targeting the *lectin-like oxidized low-density* lipoprotein receptor LOX-1.** By binding to LOX-1 and blocking its function, gocdacimab effectively reduces the level of free soluble LOX-1, thereby inhibiting key pathological processes such as lipid accumulation, foam cell formation, and vascular wall inflammation. Gocdacimab can interfere with atherosclerosis-related mechanisms, and it is used for research on atherosclerosis, and type 2 diabetes mellitus .

HY-P99793

Orticumab MLDL1278A	LDLR	Inflammation/Immunology
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized **low-density lipoproteins (oxLDL**). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement .

HY-P99822

Recaticimab SHR-1209	PCSK9	Metabolic Disease
Recaticimab (SHR-1209) is a humanized IgG1 mAb that selectively targets PCSK9. Recaticimab reduces low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), triglyceride (TG), and lipoprotein(a) levels. Recaticimab can be used for hyperlipidemia research .

Cat. No.	Nom du produit	Category	Target	Chemical Structure

HY-113046

5-Methyltetrahydrofolic acid Maximum Cited Publications 9 Publications Verification 5-Methyl THF; 5-MTHF	Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
5-Methyltetrahydrofolic acid (5-Methyl THF) is the main circulating form of folic acid in the body and is involved in a variety of biochemical reactions. 5-Methyltetrahydrofolic acid regulates cardiovascular function by increasing the production of endothelin-1 (ET-1) in low-density lipoprotein-treated endothelial cells and can be used in the study of cardiovascular diseases .

HY-112540B

Acetoacetic acid sodium	Human Gut Microbiota Metabolites Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Acetoacetic acid sodium is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid sodium induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid sodium can be used to study metabolic diseases .

HY-N0483

Phillygenin 4 Publications Verification Phillygenol; Epipinoresinol methyl ether; (+)-Phillygenin	Monophenols Oleaceae Classification of Application Fields Lignans Other Diseases Phenols Phenylpropanoids Forsythia suspensa (Thunb.) Vahl Plants Disease Research Fields Source Classification	Reactive Oxygen Species (ROS)
Phillygenin (Phillygenol) is an active ingredient from Forsythia with many medicinal properties, such as antioxidant, reducing blood lipid, inhibition of low density lipoprotein oxidation.

HY-112540

Acetoacetic acid 4 Publications Verification	Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Source Classification	Endogenous Metabolite
Acetoacetic acid is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid can be used to study metabolic diseases .

HY-N2118

Bilobetin 2 Publications Verification	Flavonoids Ginkgoaceae Classification of Application Fields Phenols Polyphenols Metabolic Disease Plants Biflavones Ginkgo biloba Disease Research Fields Source Classification	PPAR PKA Akt p38 MAPK ERK
Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity .

HY-W510159

5-O-Methylembelin	Lysimachia vulgarisL. Coumarins Phenylpropanoids Plants Primulaceae Source Classification	PCSK9
5-O-Methylembelin is a natural isocoumarin that inhibits PCSK9, *inducible degrader of the low-density* lipoprotein receptor (IDLR), and sterol regulatory element binding protein 2 (SREBP2)** mRNA expression .

HY-N0627

Kaempferol-7-O-β-D-glucopyranoside	Flavonols Structural Classification Flavonoids other families Classification of Application Fields Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields Source Classification	LDLR
Kaempferol-7-O-β-D-glucopyranoside is a flavonoid glycoside. Kaempferol-7-O-β-D-glucopyranoside exists in the root bark of Cudrania tricuspidata. Kaempferol-7-O-β-D-glucopyranoside inhibits Cu ²⁺-induced lipid peroxidation of low-density lipoprotein. Kaempferol-7-O-β-D-glucopyranoside possesses antioxidant activity and scavenges DPPH free radicals .

HY-N0594

Deacetylasperulosidic Acid	Structural Classification Iridoids Classification of Application Fields Terpenoids Rubiaceae Plants Morinda officinalis How Inflammation/Immunology Disease Research Fields Source Classification	SOD Interleukin Related TNF Receptor
Deacetylasperulosidic Acid is an orally active antioxidant. Deacetylasperulosidic Acid exerts a definite in vivo antioxidant effect and alleviates oxidative stress injury by enhancing SOD activity. In atopic dermatitis models, Deacetylasperulosidic Acid corrects Th2-skewed immune imbalance and reduces allergy-related factors; in immunosuppression models, it activates cellular immunity, enhances NK cell activity and IL-2 production. Deacetylasperulosidic Acid can be used in the research of atopic dermatitis .

HY-112540A

Acetoacetic acid lithium 4 Publications Verification	Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Acetoacetic acid lithium is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid lithium induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid lithium can be used to study metabolic diseases .

HY-N0120

(E/Z)-Polydatin (E/Z)-Piceid	Structural Classification Stilbenes Classification of Application Fields Polygonaceae Reynoutria japonica Houtt. Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields Source Classification	Drug Isomer
(E/Z)-Polydatin ((E/Z)-Piceid) is a mixture of the E/Z configurations of Polydatin (HY-N0120A). Polydatin can be isolated from Polygonum cuspidatum, grapes, peanuts, red wine, hop pellets, cocoa-containing products and chocolate products. Polydatin exhibits multiple biological properties, such as anti-platelet aggregation, anti-low-density lipoprotein oxidation, cardioprotective activity, anti-inflammatory and immunomodulatory functions. Polydatin shows favorable cytotoxic effects against various tumor cell lines, including cervical cancer cells, liver cancer cells, and nasopharyngeal carcinoma cells .

HY-126356

1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine	Structural Classification Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Lipid Source Classification	Liposome
1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine is a major phospholipid in low-density lipoprotein and belongs to the group of 1-acyl phosphatidylcholines. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine does not induce morphological changes in washed human platelets. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine can be used for the research of atherosclerosis and thrombotic diseases .

HY-W007347

1,2-Cyclohexanedione	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Biochemical Assay Reagents LDLR
1,2-Cyclohexanedione is an arginine modification reagent. 1,2-Cyclohexanedione interferes with the degradation of low-density lipoprotein by modifying the arginine group in apolipoprotein. 1,2-Cyclohexanedione can be used in the research of familial hypercholesterolemia .

HY-N5015

Rosmanol 1 Publications Verification	Classification of Application Fields Paramacrolobium coeruleum (Taub.) J.Léonard Labiatae Phenols Polyphenols Plants Disease Research Fields Source Classification Cancer	COX
Rosmanol could inhibit the oxidation of low density lipoprotein (LPL) and significantly inhibit lipopolysaccharide induced iNOS and COX-2 expression, with anti-inflammatory effect.

HY-113269

alpha-CEHC 1 Publications Verification	Microorganisms Source Classification	Drug Metabolite
alpha-CEHC is a water-soluble metabolite of alpha-tocopherol (α-TOH) with potential antioxidant activity. alpha-CEHC slightly inhibits macrophage-induced low-density lipoprotein (LDL) oxidation, and its inhibitory potency is concentration-dependent .

HY-N6738

Bafilomycin B1 1 Publications Verification	Infection Structural Classification Microorganisms Macrolide Antibiotics Classification of Application Fields Antibiotics Antibacterial Disease Research Disease Research Fields Source Classification	Antibiotic Bacterial Fungal Proton Pump
Bafilomycin B1 is a macrolide antibiotic that can be isolated from mycelium of Streptomyces gresuis. Bafilomycin B1 is neuroprotective against Chloroquine (HY-17589A)-induced death. Bafilomycin B1 is a structural analog of Bafilomycin A1 and has the ability to inhibit V-ATPase. Bafilomycin B1 inhibits significantly the oxidized low density lipoprotein (LDL)-induced accumulation of lipid droplets .

HY-N2339

Cholesteryl behenate 1 Publications Verification Cholesteryl docosanoate; Cholesterol behenate	Structural Classification Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Lipid Steroids Source Classification	Endogenous Metabolite
Cholesteryl behenate is a cholesterol ester associated with the neutral core of low density lipoprotein Receptor-LDL complexes are taken up by lysosomes and hydrolyzed to release cholesterol from the esters.

HY-N15706

Luteolin-7-O-β-D-glucuronide methyl ester	Flavonoids Astragalus laxmannii Jacq. Flavones Labiatae Plants Source Classification	LDLR
Luteolin-7-O-β-D-glucuronide methyl ester is a flavonoid with antioxidative activity. Luteolin-7-O-β-D-glucuronide methyl ester exhibits potent antioxidative activity with an IC₅₀ of 3.05 μg/mL in the NBT superoxide scavenging assay. Luteolin-7-O-β-D-glucuronide methyl ester inhibits LDL oxidation induced by Cu ²⁺ with the IC₅₀ value is 71.13 μg/mL .

HY-W747992

Indicaxanthin	Structural Classification Productos naturales Cactaceae Opuntia ficus-indica (L.) Mill. Plants Source Classification	Endogenous Metabolite
Indicaxanthin is a natural water-soluble betalain, presenting a yellow-orange color. Indicaxanthin possesses free radical scavenging ability and can inhibit lipid peroxidation, reducing the formation of malondialdehyde (MDA). Indicaxanthin can be used in the research of cardiovascular diseases and diabetes .

HY-112540AR

Acetoacetic acid lithium (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Endogenous Metabolite Reference Standards
Acetoacetic acid (lithium) (Standard) is the analytical standard of Acetoacetic acid (lithium). This product is intended for research and analytical applications. Acetoacetic acid lithium is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid lithium induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid lithium can be used to study metabolic diseases .

HY-N5015R

Rosmanol (Standard)	Paramacrolobium coeruleum (Taub.) J.Léonard Labiatae Phenols Polyphenols Plants Source Classification	Reference Standards COX
Rosmanol (Standard) is the analytical standard of Rosmanol. This product is intended for research and analytical applications. Rosmanol could inhibit the oxidation of low density lipoprotein (LPL) and significantly inhibit lipopolysaccharide induced iNOS and COX-2 expression, with anti-inflammatory effect.

HY-N2118R

Bilobetin (Standard)	Structural Classification Flavonoids Ginkgoaceae Phenols Polyphenols Plants Biflavones Ginkgo biloba Source Classification	Reference Standards PPAR PKA Akt p38 MAPK ERK
Bilobetin (Standard) is the analytical standard of Bilobetin. This product is intended for research and analytical applications. Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity .

HY-N8353

Stachybotramide	Productos naturales Microorganisms Source Classification	Others
Stachybotramide is a natural fungal metabolite with the property of modulating the activity of cholesteryl ester transfer protein (CETP). Stachybotramide stimulates the transfer of cholesteryl esters (CE) from high-density lipoprotein (HDL) to very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL), increasing the transfer efficiency by 1.3- to 1.5-fold. Stachybotramide slightly reduced the transfer of cholesteryl esters from LDL and VLDL to HDL at 0.5 mM. The effect of Stachybotramide on the transfer of triglycerides (TG) from HDL was not significant. By these results, Stachybotramide was shown to preferentially stimulate the CETP-mediated transfer of cholesteryl esters from HDL to VLDL and LDL .

HY-N12385

Hispaglabridin B (R)-Hispaglabridin B	Structural Classification Productos naturales Glycyrrhiza glabra Linn. Leguminosae Plants Source Classification	FOXO
Hispaglabridin B is an anti-oxidant agent that can be isolated from Glycyrrhiza glabra. Hispaglabridin B exhibits potent peroxynitrite scavenging activity with an IC₅₀ of 3.2 μM, and shows activity in a low-density lipoprotein (LDL) oxidation system . Hispaglabridin B is also a FoxO1 inhibitor . Hispaglabridin B improves muscle wasting by inhibiting catabolism in vivo and in vitro.

HY-182569

FR 111142	Structural Classification Productos naturales Microorganisms Source Classification	VEGFR
FR 111142 is an angiogenesis inhibitor (IC₅₀ = 18.4 μM) and has anti-inflammatory activity (IC₅₀ = 20.6 μM). FR 111142 inhibits capillary-like tube formation as well as nitric oxide production in LPS (HY-D1056)-activated murine macrophages. FR 111142 enhances catabolism of low-density lipoprotein (LDL). FR 111142 does not induce significant cytotoxicity in human endothelial progenitor cells, nor affect cell viability of murine macrophages. FR 111142 can be used for the research of cancer, inflammatory diseases .

Species:	Human (15) Rat (2) Mouse (2) Cynomolgus (1)
Tag:	His (16) Strep (3) Avi (1) Myc (1) Fc (4)
Source:	HEK293 (19) E. coli (1)

Cat. No.	Compare	Nom du produit	Species	Source	Image

HY-P73272

	LDLR Protein, Mouse (HEK293, His) low-density lipoprotein receptor; LDLR; LDL Receptor	Mouse	HEK293
	LDLR Protein crucially binds to LDL, transporting cholesterol through endocytosis. Clustering into clathrin-coated pits initiates internalization. Interactions with DAB2, LDLRAP1, ARRB1, SNX17, and immature PCSK9 contribute to its functional versatility. The NPXY motif interaction is impaired by tyrosine phosphorylation. LDLR Protein, Mouse (HEK293, His) is the recombinant mouse-derived LDLR protein, expressed by HEK293 , with C-His labeled tag.

HY-P76125

	VLDLR Protein, Human (HEK293, His) Very low-density lipoprotein receptor; VLDL-R	Human	HEK293
	The VLDLR protein is a multifunctional receptor that mediates energy metabolism by binding VLDL and transporting it into cells. It interacts with Reelin/RELN, APOE-containing ligands and clusterin/CLU. VLDLR Protein, Human (HEK293, His) is the recombinant human-derived VLDLR protein, expressed by HEK293 , with C-His labeled tag.

HY-P72392

	LDLR Protein, Human (Biotinylated, HEK293, Avi-His) low-density lipoprotein Receptor; LDL Receptor; LDLR	Human	HEK293
	LDLR Protein plays a pivotal role in cholesterol homeostasis, binding to LDL and mediating cellular uptake through endocytosis. Clustering into clathrin-coated pits is essential for internalization. In microbial infection, LDLR acts as a receptor for hepatitis C virus in hepatocytes, emphasizing its dual functionality in cholesterol metabolism and the cellular response to viral infections. LDLR Protein, Human (Biotinylated, HEK293, Avi-His) is the recombinant human-derived LDLR protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag.

HY-P70235

	LDLR Protein, Human (HEK293, His) 2 Publications Verification rHulow-density lipoprotein receptor/LDLR, His; low-density lipoprotein Receptor; LDL Receptor; LDLR	Human	HEK293
	LDLR Protein plays a pivotal role in cholesterol homeostasis, binding to LDL and mediating cellular uptake through endocytosis. Clustering into clathrin-coated pits is essential for internalization. In microbial infection, LDLR acts as a receptor for hepatitis C virus in hepatocytes, emphasizing its dual functionality in cholesterol metabolism and the cellular response to viral infections. LDLR Protein, Human (HEK293, His) is the recombinant human-derived LDLR protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P76477

	LRP-11 Protein, Human (HEK293, His) low-density lipoprotein receptor-related protein 11; LRP-11	Human	HEK293
	Low-density lipoprotein receptor-related protein 11 is a member of LRP family and it acts as a tumour promoter in cervical cancer. Low-density lipoprotein receptor-related protein 11 enables phosphoprotein binding activity. LRP-11 Protein, Human (HEK293, His) is the recombinant human-derived LRP-11 protein, expressed by HEK293 , with C-His labeled tag.

HY-P73838

	LDLR Protein, Mouse (Biotinylated, A23V, C27G, HEK293, His) low-density lipoprotein receptor; LDLR; LDL Receptor	Mouse	HEK293
	LDLR Protein crucially binds to LDL, transporting cholesterol through endocytosis. Clustering into clathrin-coated pits initiates internalization. Interactions with DAB2, LDLRAP1, ARRB1, SNX17, and immature PCSK9 contribute to its functional versatility. The NPXY motif interaction is impaired by tyrosine phosphorylation. LDLR Protein, Mouse (Biotinylated, A23V, C27G, HEK293, His) is the recombinant mouse-derived LDLR protein, expressed by HEK293 , with C-His labeled tag and A23V, C27G mutation.

HY-P77057A

	LDLRAD3 Protein, Human (HEK293, hFc) low-density lipoprotein receptor class A domain-containing protein 3; LRAD3	Human	HEK293
	LDLRAD3 protein significantly affects the processing of amyloid precursor protein (APP), possibly reducing soluble APP-α (sAPP-α) and increasing the production of amyloid P3 peptide. Suggested regulation of ITCH and NEDD4 E3 ligases. LDLRAD3 Protein, Human (HEK293, hFc) is the recombinant human-derived LDLRAD3, expressed by HEK293, with C-hFc labeled tag.

HY-P76476

	LRP-10 Protein, Human (HEK293, His) low-density lipoprotein receptor-related protein 10; LRP-10; MSTP087; SP220	Human	HEK293
	The LRP-10 protein is a possible receptor that may mediate internalization and/or signaling of lipophilic molecules.It is speculated that LRP-10 can promote the uptake of lipoprotein APOE in the liver and may play a role in lipid metabolism and processes related to lipoprotein transport.LRP-10 Protein, Human (HEK293, His) is the recombinant human-derived LRP-10 protein, expressed by HEK293 , with C-His labeled tag.

HY-P77057

	LDLRAD3 Protein, Human (HEK293, Fc, solution) low-density lipoprotein receptor class A domain-containing protein 3; LRAD3	Human	HEK293
	LDLRAD3 protein significantly affects the processing of amyloid precursor protein (APP), possibly reducing soluble APP-α (sAPP-α) and increasing the production of amyloid P3 peptide. Suggested regulation of ITCH and NEDD4 E3 ligases. LDLRAD3 Protein, Human (HEK293, Fc, solution) is the recombinant human-derived LDLRAD3 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P76475

	LRP-10 Protein, Human (HEK293, Fc) low-density lipoprotein receptor-related protein 10; LRP-10; MSTP087; SP220	Human	HEK293
	The LRP-10 protein is a possible receptor that may mediate internalization and/or signaling of lipophilic molecules.It is speculated that LRP-10 can promote the uptake of lipoprotein APOE in the liver and may play a role in lipid metabolism and processes related to lipoprotein transport.LRP-10 Protein, Human (HEK293, Fc) is the recombinant human-derived LRP-10 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P73835

	LOX-1/OLR1 Protein, Rat (HEK293, His) Oxidized low-density lipoprotein receptor 1; LOX-1; OLR1; CLEC8A	Rat	HEK293
	The LOX-1/OLR1 protein plays an important role as a receptor that recognizes, internalizes, and degrades oxidatively modified low-density lipoprotein (oxLDL), a marker of atherosclerosis, in vascular endothelial cells. OxLDL induces endothelial dysfunction, triggering pro-inflammatory responses, oxidative conditions, and apoptosis. LOX-1/OLR1 Protein, Rat (HEK293, His) is the recombinant rat-derived LOX-1/OLR1 protein, expressed by HEK293 , with N-His labeled tag.

HY-P76474

	LOX-1/OLR1 Protein, Cynomolgus (HEK293, His) Oxidized low-density lipoprotein receptor 1; LOX-1; OLR1; CLEC8A	Cynomolgus	HEK293
	OLR1 is a type II membrane glycoprotein belonging to C-type lectin family with a short N-terminal cytoplasmic tail and a long C-terminal extracellular domain. OLR1 binds ox-LDL, delipidated, and solubilized ox-LDL. LOX-1/OLR1 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived LOX-1/OLR1 protein, expressed by HEK293 , with N-His labeled tag.

HY-P73836

	LOX-1/OLR1 Protein, Rat (HEK293, Fc) Oxidized low-density lipoprotein receptor 1; LOX-1; OLR1; CLEC8A	Rat	HEK293
	The LOX-1/OLR1 protein plays an important role as a receptor that recognizes, internalizes, and degrades oxidatively modified low-density lipoprotein (oxLDL), a marker of atherosclerosis, in vascular endothelial cells. OxLDL induces endothelial dysfunction, triggering pro-inflammatory responses, oxidative conditions, and apoptosis. LOX-1/OLR1 Protein, Rat (HEK293, Fc) is the recombinant rat-derived LOX-1/OLR1 protein, expressed by HEK293 , with N-hFc labeled tag.

HY-P704737

	LRP2/Megalin Protein, Human (HEK293, His) low-density lipoprotein receptor-related protein 2; LRP2; Glycoprotein 330 (gp330); Megalin; LRP-2	Human	HEK293
	LRP2/Megalin Protein, Human (HEK293, His) is the recombinant human-derived LRP2/Megalin protein, expressed by HEK293, with C-His tag.

HY-P70946

	LRP-12 Protein, Human (HEK293, His) low-density lipoprotein Receptor-Related Protein 12; LRP-12; Suppressor of Tumorigenicity 7 Protein; LRP12; ST7	Human	HEK293
	LRP-12, a probable receptor, potentially facilitates the internalization of lipophilic molecules and signal transduction. It may function as a tumor suppressor and interacts with proteins RACK1, ZFYVE9, and NMRK2. LRP-12 Protein, Human (HEK293, His) is the recombinant human-derived LRP-12 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P705715

	LRP2/Megalin Protein, Human (214a.a, His, Myc) low-density lipoprotein receptor-related protein 2; LRP2; Glycoprotein 330 (gp330); Megalin; LRP-2	Human	E. coli
	LRP2/Megalin Protein, Human (214a.a, His, Myc) is the recombinant human-derived LRP2/Megalin protein, expressed by E. coli, with N-His and C-Myc tag.

HY-P705714

	LRP2/Megalin Protein, Human (413a.a, HEK293, His-StrepII) low-density lipoprotein receptor-related protein 2; LRP2; Glycoprotein 330 (gp330); Megalin; LRP-2	Human	HEK293
	LRP2/Megalin Protein, Human (413a.a, HEK293, His-StrepⅡ) is the recombinant human-derived LRP2/Megalin protein, expressed by HEK293, with C-His and C-StrepⅡ tag.

HY-P705712

	LRP2/Megalin Protein, Human (282a.a, HEK293, His-StrepⅡ) low-density lipoprotein receptor-related protein 2; LRP2; Glycoprotein 330 (gp330); Megalin; LRP-2	Human	HEK293
	LRP2/Megalin Protein, Human (282a.a, HEK293, His-StrepⅡ) is the recombinant human-derived LRP2/Megalin protein, expressed by HEK293, with C-His and C-StrepⅡ tag.

HY-P705713

	LRP2/Megalin Protein, Human (325a.a, HEK293, His-StrepⅡ) low-density lipoprotein receptor-related protein 2; LRP2; Glycoprotein 330 (gp330); Megalin; LRP-2	Human	HEK293
	LRP2/Megalin Protein, Human (325a.a, HEK293, His-StrepⅡ) is the recombinant human-derived LRP2/Megalin protein, expressed by HEK293, with C-His and C-StrepⅡ tag.

HY-P71180

	LOX-1/OLR1 Protein, Human (HEK293, His) Oxidized low-density lipoprotein Receptor 1; Ox-LDL Receptor 1; C-Type Lectin Domain Family 8 Member A; Lectin-Like Oxidized LDL Receptor 1; LOX-1; Lectin-Like oxLDL Receptor 1; hLOX-1; Lectin-Type Oxidized LDL Receptor 1; OLR1; CLEC8A; LOX1	Human	HEK293
	The OLR1 protein is a receptor on vascular endothelial cells that plays a key role in the recognition, internalization, and degradation of oxidatively modified low-density lipoprotein (oxLDL). As a marker of atherosclerosis, oxLDL induces activation of vascular endothelial cells, leading to proinflammatory responses, oxidative conditions, and apoptosis. OLR1 Protein, Human (HEK293, His) is the recombinant human-derived OLR1 protein, expressed by HEK293 , with C-6*His labeled tag.

Compare Products


Products	En stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / En stock - + Ajouter au chariot Obtenir un devis

Cat. No.	Nom du produit	Chemical Structure

HY-B0144AS1

Pitavastatin-d5 sodium
Pitavastatin-d₅ (sodium) is the deuterium labeled Pitavastatin sodium. Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity.

HY-113046S1

5-Methyltetrahydrofolic acid-13C6

5-Methyltetrahydrofolic acid- ¹³C₆ (5-Methyl THF- ¹³C₆) is ¹³C labeled 5-Methyltetrahydrofolic acid. 5-Methyltetrahydrofolic acid (5-Methyl THF) is the main circulating form of folic acid in the body and is involved in a variety of biochemical reactions. 5-Methyltetrahydrofolic acid regulates cardiovascular function by increasing the production of endothelin-1 (ET-1) in low-density lipoprotein-treated endothelial cells and can be used in the study of cardiovascular diseases .

HY-17504AS1

Rosuvastatin-d6

Rosuvastatin-d₆ (ZD 4522-d₆) is deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC₅₀ of 11 nM. Rosuvastatin potently blocks hERG current with an IC₅₀ of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-W015600S

2-Acetamidophenol-d3

2-Acetamidophenol-d₃ (Orthocetamol-d₃) is the deuterium labeled 2-Acetamidophenol (HY-W015600). 2-Acetamidophenol (Orthocetamol) is a regulator that targets ferroptosis and glutathione metabolic pathways, is the ortho-regioisomer of Paracetamol (HY-66005). 2-Acetamidophenol has anti-atherosclerotic activity, and inhibiting total cholesterol (TC) and triglyceride (TG) in a zebrafish hyperlipidemia model with IC50s for 30 μM and 40 μM, respectively. 2-Acetamidophenol upregulates the expression of glutathione synthesis-related genes (such as GCLC, GCLM, GSS) and iron ion transport genes (such as FPN1, FTH), reduces the accumulation of intracellular reactive oxygen species (ROS) and ferrous ions (Fe2+), and enhances the activity of glutathione peroxidase GPX4, thereby inhibiting macrophage phagocytosis of oxidized low-density lipoprotein (ox-LDL) and foam cell formation .

HY-17504BS1

Rosuvastatin-d6 sodium

Rosuvastatin-d₆ sodium is deuterium labeled Rosuvastatin sodium (HY-17504B). Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC₅₀ of 195 nM. Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.

HY-17504BS2

Rosuvastatin-13C,d3 sodium

Rosuvastatin- ¹³C,d₃ sodium is ¹³C and deuterated labeled Rosuvastatin sodium (HY-17504B). Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC₅₀ of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-17504AS

Rosuvastatin-d3

Rosuvastatin-d₃ (ZD 4522-d₃) is a deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC₅₀ of 11 nM . Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC₅₀ of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals .

HY-B0144S

Pitavastatin-d4 hemicalcium

Pitavastatin-d₄ (hemicalcium) is deuterium labeled Pitavastatin (Calcium). Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity[1][2][3].

HY-B0144AS3

Pitavastatin-d4-1 sodium

Pitavastatin-d₄-1 (NK-104-d₄-1) sodium is the deuterium labeled Pitavastatin sodium (HY-B0144B). Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC₅₀ of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .

HY-B0374S

Moxonidine-d4

Moxonidine-d₄ (BDF5895-d₄) is the deuterium labeled Moxonidine (HY-B0374). Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I₁-R) agonist. Moxonidine activates imidazoline I₁ receptors and α₂ adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis .

HY-109523S

Cerivastatin-d3 sodium

Cerivastatin-d₃ sodium is deuterated labeled Cerivastatin sodium (HY-109523). Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .

HY-B0374S1

Moxonidine-d7

Moxonidine-d₇ is deuterated labeled Moxonidine (HY-B0374). Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I₁-R) agonist. Moxonidine activates imidazoline I₁ receptors and α₂ adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis .

HY-B0374AS

Moxonidine-13C,d3 hydrochloride

Moxonidine- ¹³C,d₃ hydrochloride is ¹³C and deuterated labeled Moxonidine hydrochloride (HY-B0374A). Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I₁-R) agonist. Moxonidine activates imidazoline I₁ receptors and α₂ adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis .

HY-B0374S2

Moxonidine-d3

Moxonidine-d₃ (BDF5895-d₃) is deuterium labeled Moxonidine (HY-B0374). Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I₁-R) agonist. Moxonidine activates imidazoline I₁ receptors and α₂ adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis .

HY-W041171S

3-Chloro-L-tyrosine-13C6
3-Chloro-L-tyrosine- ¹³C₆ is the ¹³C labeled 3-Chloro-L-tyrosine . 3-Chloro-L-tyrosine is a specific marker of myeloperoxidase-catalyzed oxidation, and is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima .

HY-126356S

1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine-d11

1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine-d₁₁ is the deuterium labeled 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (HY-126356). 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine is a major phospholipid in low-density lipoprotein and belongs to the group of 1-acyl phosphatidylcholines. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine does not induce morphological changes in washed human platelets. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine can be used for the research of atherosclerosis and thrombotic diseases .

HY-113046S2

5-Methyltetrahydrofolic acid-d4

5-Methyltetrahydrofolic acid-d₄ (5-Methyl THF-d₄) is the deuterium labeled 5-Methyltetrahydrofolic acid (HY-113046). 5-Methyltetrahydrofolic acid (5-Methyl THF) is the main circulating form of folic acid in the body and is involved in a variety of biochemical reactions. 5-Methyltetrahydrofolic acid regulates cardiovascular function by increasing the production of endothelin-1 (ET-1) in low-density lipoprotein-treated endothelial cells and can be used in the study of cardiovascular diseases .

Host:	Mouse (5) Rabbit (13)
Reactivity:	Human (16) Rat (12) Mouse (11) Rabbit (1) human (1) Hamster (2)
Application:	IHC-P (11) ICC/IF (4) IF-Tissue (6) IP (3) WB (14) IHC-F (6) FC (3) ELISA (3)
Isotype:	IgG (15) IgG1 (2) IgG2a (1)
Conjugation:	Non-conjugated (18) Biotin (2)
Clonality:	Polyclonal (2) polyclonal (1) Monoclonal (9) Recombinant (7)
Modification:	Unmodified (13)

Cat. No.	Compare	Nom du produit	Application	Reactivity	Image

HY-P81166

	ox-LDL Antibody ox-LDL: LDL (Copper oxidized); Cu2SO4 oxidized low density lipoprotein; oxidized low density lipoprotein; low density lipoprotein; MDA oxidized LDL; MDA oxidized low density lipoprotein. 氧化型低密度脂蛋白;	ELISA, IHC-P, IHC-F, FC, ICC/IF	Human
	ox-LDL Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to ox-LDL.

HY-P86713

	ox-LDL Antibody (YA6405) ox-LDL: LDL(Copper oxidized); Cu2SO4 oxidized low density lipoprotein; oxidized low density lipoprotein; low density lipoprotein; MDA oxidized LDL; MDA oxidized low density lipoprotein.	IHC-P, IHC-F, IF-Tissue	Human, Mouse, Rat
	ox-LDL Antibody (YA6405) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to ox-LDL.

HY-P86713A

	ox-LDL Antibody (YA6405)(PBS only) ox-LDL: LDL(Copper oxidized); Cu2SO4 oxidized low density lipoprotein; oxidized low density lipoprotein; low density lipoprotein; MDA oxidized LDL; MDA oxidized low density lipoprotein.	IHC-P, IHC-F, IF-Tissue	Human, Mouse, Rat
	ox-LDL Antibody (YA6405) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to ox-LDL.

HY-P83717

	LDLR Antibody (YA3452) LDLR_HUMAN; low-density lipoprotein receptor; LDL receptor; FH; FHC; FHCL1; LDLCQ2; low density lipoprotein receptor;	WB, IHC-P	Human, Mouse
	LDLR Antibody (YA3452) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to LDLR.

HY-P81172

	LOX 1 Antibody Lectin-type oxidized LDL receptor 1; OLR1; lectin-like low density lipoprotein receptor-1; Oxidized low-density lipoprotein receptor 1; Ox-LDL receptor 1; Lectin-like oxidized LDL receptor 1; Lectin-like oxLDL receptor 1; LOX-1; BLOX1; Contains: Oxidized low-density lipoprotein receptor 1, soluble form A; Oxidized low-density lipoprotein receptor 1, soluble form B; OLR1_HUMAN.	WB, IHC-P, ICC/IF, FC	Human, Rat, Rabbit
	LOX 1 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to LOX 1.

HY-P810758

	Phospho-LRP6 (Ser1490) Antibody (YA10001) low-density lipoprotein receptor-related protein 6, LRP-6, LRP6	WB	Human
	Phospho-LRP6 (Ser1490) Antibody (YA10001) is a Rabbit-derived and non-conjugated IgG Monoclonal, Recombinant antibody, targeting to Phospho-LRP6 (Ser1490).

HY-P82383

	ApoER2 Antibody (YA2128) LRP8; APOER2; low-density lipoprotein receptor-related protein 8; LRP-8; Apolipoprotein E receptor 2	WB, IP	Human, Rat, Hamster
	ApoER2 Antibody (YA2128) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ApoER2.

HY-P83131

	Lrp2/Megalin Antibody (YA2876) low-density lipoprotein receptor-related protein 2; LRP-2; Glycoprotein 330; gp330; Megalin; LRP2; DBS	WB	Human, Mouse, Rat
	Lrp2/Megalin Antibody (YA2876) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Lrp2/Megalin.

HY-P83746

	Lrp2/Megalin Antibody (YA3473) low-density lipoprotein receptor-related protein 2; LRP-2; Glycoprotein 330; gp330; Megalin; LRP2; DBS	WB, IHC-P, IF-Tissue	Human, Mouse, Rat
	Lrp2/Megalin Antibody (YA3473) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Lrp2/Megalin.

HY-P82383A

	ApoER2 Antibody (YA2128)(PBS only) LRP8; APOER2; low-density lipoprotein receptor-related protein 8; LRP-8; Apolipoprotein E receptor 2	WB, IP	Human, Rat, Hamster
	ApoER2 Antibody (YA2128) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ApoER2.

HY-P87412A

	LRP4 Antibody (YA7100)(PBS only) KIAA0816, LRP10, MEGF7, LRP4, low-density lipoprotein receptor-related protein 4, LRP-4, Multiple epidermal growth factor-like domains 7	FC, ELISA	Human
	LRP4 Antibody (YA7100) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to LRP4.

HY-P86948

	LRP4 Antibody (YA6641) KIAA0816 antibody; LDLR dan antibody; low density lipoprotein receptor related protein 4 antibody; low-density lipoprotein receptor-related protein 4 antibody; LRP-4 antibody; LRP10 antibody; Lrp4 antibody; LRP4_HUMAN antibody; MEGF7 antibody; Multiple epidermal growth factor like domains 7 antibody; KIAA0816 antibody; LDLR dan antibody; low density lipoprotein receptor related protein 4 antibody; low-density lipoprotein receptor-related protein 4 antibody; LRP-4 antibody; LRP10 antibody; Lrp4 antibody; LRP4_HUMAN antibody; MEGF7 antibody; Multiple epidermal growth factor like domains 7 antibody; Multiple epidermal growth factor-like domains 7 antibody;	WB	Mouse, Rat
	LRP4 Antibody (YA6641) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to LRP4.

HY-P86698

	LRP2 Antibody (YA6390) LRP2_HUMAN; low-density lipoprotein receptor-related protein 2; LDL receptor related protein 2; DBS; GP330; LRP-2; Glycoprotein 330(gp330); Megalin;	IHC-P, WB, IF-Tissue, IHC-F, ICC/IF	Mouse, Rat, Human
	LRP2 Antibody (YA6390) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to LRP2.

HY-P86698A

	LRP2 Antibody (YA6390)(PBS only) LRP2_HUMAN; low-density lipoprotein receptor-related protein 2; LDL receptor related protein 2; DBS; GP330; LRP-2; Glycoprotein 330(gp330); Megalin;	IHC-P, WB, IF-Tissue, IHC-F, ICC/IF	Mouse, Rat, Human
	LRP2 Antibody (YA6390) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to LRP2.

HY-P82565

	SorLA Antibody (YA2310) SORL1; C11orf32; Sortilin-related receptor; low-density lipoprotein receptor relative with 11 ligand-binding repeats; LDLR relative with 11 ligand-binding repeats; LR11; SorLA-1; Sorting protein-related receptor containing LDLR class A repe	WB, IHC-P	Human, Mouse, Rat
	SorLA Antibody (YA2310) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SorLA.

HY-P85374

	SorLA Antibody (YA5066) SORL1; C11orf32; Sortilin-related receptor; low-density lipoprotein receptor relative with 11 ligand-binding repeats; LDLR relative with 11 ligand-binding repeats; LR11; SorLA-1; Sorting protein-related receptor containing LDLR class A repe	WB, IHC-P, IHC-F, IF-Tissue	Human, Mouse, Rat
	SorLA Antibody (YA5066) is a Rabbit-derived and non-conjugated monoclonal antibody, targeting to SorLA.

HY-P810504

	LOX1 Antibody CLEC8A, LOX1, OLR1, Oxidized low-density lipoprotein receptor 1, Ox-LDL receptor 1, C-type lectin domain family 8 member A, Lectin-like oxidized LDL receptor 1, Lectin-type oxidized LDL receptor 1, LOX-1, Lectin-like oxLDL receptor 1, hLOX-1	WB, IHC-P	Human, Mouse
	LOX1 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to LOX1.

HY-P89589

	Corin Antibody (YA8933) Crn, Lrp4, Corin, Atrial natriuretic peptide-converting enzyme, low density lipoprotein receptor-related protein 4, Pro-ANP-converting enzyme	WB, IP, ELISA	human
	Corin Antibody (YA8933) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Corin.

Compare Products


Products	En stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / En stock - + Ajouter au chariot Obtenir un devis

Cat. No.	Nom du produit		Classification

HY-N2339

Cholesteryl behenate 1 Publications Verification Cholesteryl docosanoate; Cholesterol behenate		Cholesterol
Cholesteryl behenate is a cholesterol ester associated with the neutral core of low density lipoprotein Receptor-LDL complexes are taken up by lysosomes and hydrolyzed to release cholesterol from the esters.

Demande en ligne

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Civilité			Country or Region *
Nom du demandeur *			Nom de l'organisation *
Department *
Adresse e-mail *			Nom du produit *
Cat. No.			Requested quantity *
Numéro de téléphone *
Remarques

Demande en ligne

Inquiry Information

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

low-density lipoprotein

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Protéines recombinantes

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Natural
Products